|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |
| Brief Title † | A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV |
| Official Title † | Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy |
| Brief Summary | To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy. |
| Detailed Description | Any physician qualified to treat pediatric AIDS patients may enroll patients in this study. |
| Study Phase | Phase III |
| Study Type † | Interventional |
| Study Design † | Treatment, Open Label, Efficacy Study |
| Primary Outcome Measure † | |
| Secondary Outcome Measure † | |
| Condition † | HIV Infections Chickenpox |
| Intervention † | Drug: Sorivudine |
| MEDLINE PMIDs | |
| Links | BMS Clinical Trials Disclosure ![]() For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm  ![]() |
| Recruitment Information Fields | |
| Recruitment Status † | Completed |
| Enrollment † | |
| Start Date † | |
| Completion Date | |
| Eligibility Criteria † | Inclusion Criteria Patients must have:
Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Concurrent Medication: Excluded:
Patients with the following prior condition are excluded: History of immediate hypersensitivity to nucleoside analogues. Prior Medication: Excluded:
Required:
|
| Gender | Both |
| Ages | 2 Years to 17 Years |
| Accepts Healthy Volunteers | No |
| Contacts †† | |
| Location Countries † | United States |
| Administrative Information Fields | |
| NCT ID † | NCT00002358 |
| Organization ID | 255A |
| Secondary IDs †† | AI458-903 |
| Study Sponsor † | Bristol-Myers Squibb |
| Collaborators †† | |
| Investigators † | |
| Information Provided By | Bristol-Myers Squibb |
| Verification Date | October 2007 |
| First Received Date † | November 2, 1999 |
| Last Updated Date | October 1, 2007 |